Free Trial
NYSEARCA:XPH

SPDR S&P Pharmaceuticals ETF (XPH) Price, Holdings, & News

SPDR S&P Pharmaceuticals ETF logo
$63.02 +0.95 (+1.53%)
Closing price 10/15/2026 04:10 PM Eastern
Extended Trading
$63.02 -0.01 (-0.01%)
As of 10/15/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH)

Advanced

Key Stats

Today's Range
$62.67
▼
$64.02
50-Day Range
$62.07
▼
$74.06
52-Week Range
$47.60
▼
$74.35
Volume
137,716 shs
Average Volume
110,889 shs
Market Capitalization
$456.90 million
Assets Under Management
$444.24 million
Dividend Yield
0.43%
Net Expense Ratio
0.35%
Aggregate Rating
Moderate Buy

ETF Overview

SPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Fund invests substantially all, but at least 80%, of its total assets in the securities comprising the Index. In addition, the Fund may invest in equity securities that are not included in the Index, cash and cash equivalents or money market instruments, such as repurchase agreements and money market funds. The Pharmaceuticals Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.

SPDR S&P Pharmaceuticals ETF Expenses

TypeXPHHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFs
Management Fee0.35%0.55%0.57%0.50%0.53%
Other Expenses0.00%0.52%0.53%0.60%0.54%
Total Expense0.35%0.76%0.75%0.75%0.73%
Fee Waiver0.00%-0.85%-0.67%-0.78%-0.68%
Net Expense0.35%0.58%0.63%0.57%0.60%
Receive XPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SPDR S&P Pharmaceuticals ETF and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

XPH ETF News Headlines

This Tiny Sub-$1 Gold-Silver Royalty Stock Is Ready to Run
A gold-silver royalty firm just closed the largest transaction in its history a new gold streaming deal on a producing mine. The company earns cash flow without operating a single mine, and shares still trade below $1. A major mining financier has already invested and joins the CEO in an exclusive interview.tc pixel
See More Headlines

XPH ETF - Frequently Asked Questions

SPDR S&P Pharmaceuticals ETF's stock was trading at $56.01 at the beginning of the year. Since then, XPH stock has increased by 12.5% and is now trading at $63.02.

Top institutional investors of SPDR S&P Pharmaceuticals ETF include First Citizens Bank & Trust Co. (2.35%), Avior Wealth Management LLC (0.25%), Fragasso Financial Advisors Inc (0.09%) and Farther Finance Advisors LLC (0.05%).

Shares of XPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Fund Details

Issuer
SSgA
Fund Name
SPDR S&P Pharmaceuticals ETF
Tax Classification
Regulated Investment Company
Stock Exchange
NYSEARCA
Current Symbol
NYSEARCA:XPH
Inception Date
6/19/2006
Fund Manager
Michael Feehily, Karl Schneider, Keith Richardson

Fund Focus

Asset Class
Equity
Benchmark
S&P Pharmaceuticals Select Industry Index
Category
Sector
Focus
Health Care
Development Level
Developed Markets
Region
North America
Number of Holdings
70

Fund Statistics

Assets Under Management
$444.24 million
Average Daily Volume
$210.16 thousand
Discount/Premium
-0.06%

Administrator, Advisor and Custodian

Administrator
State Street Global Advisors Funds Management, Inc.
Advisor
SSgA Funds Management, Inc.
Custodian
State Street Bank and Trust Company
Distributor
State Street Global Advisors Funds Distributors, LLC
Transfer Agent
State Street Bank and Trust Company
Trustee
N/A
Lead Market Maker
Citadel

Options

Optionable
N/A
Short Interest
587,007 shs

Miscellaneous

Beta
0.61
Creation Unit
50,000
Creation Fee
$250.00
The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Top 10 XPH Holdings

XPH Sector Exposure

XPH Industry Exposure


This page (NYSEARCA:XPH) was last updated on 10/15/2026 by MarketBeat.com Staff.
From Our Partners